米氮平与黛力新治疗胃肠功能紊乱的疗效及安全性分析  

Curative effects and safety analysis of Mirtazapine and Denixit in the treatment of gastrointestinal dysfunction

作　　者：丁兆猛 王建荣[1] Ding Zhaomeng;Wang Jianrong(The Fourth People＇s Hospital of Taizhou,Taizhou Jiangsu 22530)

机构地区：[1]江苏省泰州市第四人民医院,泰州225300

出　　处：《北方药学》2018年第11期170-171,共2页Journal of North Pharmacy

摘　　要：目的:比较米氮平和黛力新治疗胃肠功能紊乱的临床疗效及安全性。方法:选取2016年2月~2017年1月我院门诊收治的118例胃肠功能紊乱患者,随机分成3组,根据选取治疗药物的不同,分为A、B、C三组,A、B两组为治疗组,C组为对照组,A组39例(米氮平组),B组37例(黛力新组),C组42例,A组给予基础治疗+米氮平15mg,每晚口服一次,B组给予基础治疗+黛力新1片,每天早晨口服一次,C组只给予基础治疗,连续服药4周。结果:A组治疗4周后总有效率以及反酸嗳气、食后饱胀、上腹不适或疼痛改善率分别为92.3%、89.7%、94.9%、92.3%,B组分别为89.2%、91.9%、83.8%、86.5%,C组分别为85.7%、81.0%、83.3%、88.1%,3个月后复发率分别为5.1%、13.5%、16.7%,治疗组与对照组比较有显著差异(P<0.05)。结论:米氮平和黛力新治疗胃肠功能紊乱临床疗效确切,总有效率均较高,不良反应少且轻微,但停药后黛力新复发率较高,需要长期维持治疗。Objective：To compare the curative effects and safety of Mirtazapine and Denixit in the treatment of gastrointestinal dysfunction. Method：118 patients with gastrointestinal dysfunction were divided into three groups,Group A（n=39） and group B（n=37） were study groups,group C（n=42） was control group. Group A was treated with basic treatment and Mirtazapine tablets for 4 weeks, group B was treated with basic treatment and Denixit tablets for 4 weeks,and group C was treated with basic treatment only. Results：After 4 weeks treatment,the total effective rate and three-month relapse rate were 92.3% and 5.1% in group A, the results of group B were 89.2% and 13.5%,while the corresponding parameters of group C were 85.7% and 16.7%.The statistical results showed marked difference between the study group（group A and B） and the control group（P〈0.05）.Conclusion：There are exact curative effects in the treatment of gastrointestinal dysfunction by Mirtazapine and Denixit,but the recurrence rate of Denixit is higher than Mirtazapine tablets.

关 键 词：米氮平 黛力新 胃肠功能紊乱 

分 类 号：R57[医药卫生—消化系统]